Tata Consultancy Services (TCS) has launched the Advanced Drug Development (ADD) Site Feasibility Platform, which provides life sciences companies with a single, integrated platform that digitizes the site selection and activation processes, and facilitates data-driven decision-making while assessing site feasibility for multi-site clinical trials.
TCS' Site Feasibility Platform, the latest addition to the ADD suite of cloud-based clinical platforms, addresses this critical problem currently faced by life sciences companies, by leveraging the power of digital technologies to drive superior clinical outcomes.
Moreover, the platform is fully integrated with the TCS Connected Clinical Trials e-Survey Platform, providing customers with an end-to-end solution for conducting site surveys and analyzing the survey responses.
Tata Consultancy Services is an IT services, consulting and business solutions provider that has been partnering with the world’s largest businesses in their transformation journeys for the last fifty years.
| Company Name | CMP |
|---|---|
| TCS | 2581.65 |
| Infosys | 1318.60 |
| HCL Tech. | 1442.50 |
| Wipro | 204.35 |
| Tech Mahindra | 1511.85 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: